Detecting sub-clinical disease activity in patients with chronic rheumatic valvular heart disease

Aayush Kumar Singal a,1, Velayoudam Devagourou b,1, Milind Padmakar Hote b,1, Shiv Kumar Choudhary b,1, Neeraj Parakh a,1, Ruma Ray c,1, Ramakrishnan Lakshmy d,1, Ganesan Karthikeyan a,*,1

a Department of Cardiology, All India Institute of Medical Sciences (AIIMS), New Delhi, India
b Department of Cardiothoracic and Vascular Surgery, All India Institute of Medical Sciences (AIIMS), New Delhi, India
c Department of Pathology, All India Institute of Medical Sciences (AIIMS), New Delhi, India
d Department of Cardiac Biochemistry, All India Institute of Medical Sciences (AIIMS), New Delhi, India

ARTICLE INFO

Article history:
Received 5 February 2020
Received in revised form
11 October 2020
Accepted 12 February 2021
Available online 27 February 2021

Keywords:
Ga-67 scintigraphy
Interferons
Myocardial lympho-mononuclear infiltration
Rheumatic heart disease
Sub-clinical inflammation

ABSTRACT

Objective: Valve disease progression in rheumatic heart disease (RHD) is generally attributed to recurrent attacks of acute rheumatic fever (ARF). However, persistence of chronic sub-clinical inflammation remains a plausible but unproven cause. Non-invasive means to identify sub-clinical inflammation may facilitate research efforts towards understanding its contribution to disease progression. Methods: Patients with chronic RHD, without clinical evidence of ARF, undergoing elective valve surgery were enrolled. Sub-clinical inflammation was ascertained by histological evaluation of left atrial appendage and valve tissue excised during surgery. We assessed the diagnostic utility of Gallium-67 scintigraphy imaging, and inflammatory biomarkers, hsCRP, IL-2, IL-6, Tumor Necrosis Factor-Alpha (TNF-α), Interferon-gamma (IFN-γ), and Serum Amyloid A (SAA), in identifying patients with sub-clinical inflammation.

Results: Of the 93 RHD patients enrolled (mean age 34 ± 11 years, 45% females), 86 were included in final analysis. Sub-clinical inflammation was present in 27 patients (31.4%). Patients with dominant regurgitant lesions were more likely to have sub-clinical inflammation compared to those with stenotic lesions, though this association was not statistically significant (dominant regurgitant lesions vs isolated mitral stenosis: OR 3.5, 95%CI 0.68–17.96, p = 0.133). Inflammatory biomarkers were elevated in the majority of patients: hsCRP, IL-2, IL-6, TNF-α, and IFN-γ in 44%, 89%, 90%, 79%, and 81% patients, respectively. However, there was no significant association between biomarker elevation and histologically ascertained sub-clinical inflammation. Ga-67 imaging was unable to identify inflammation in the 15 patients in whom it was performed.

Conclusion: Sub-clinical inflammation is common in RHD patients. Conventional inflammatory markers are elevated in the majority, but aren’t discriminatory enough to identify the presence of histologic inflammation. © 2021 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) remain important causes of morbidity and mortality in the developing world.1,2 Acute rheumatic fever is an inflammatory disease which occurs as a sequela of Group A Streptococcal pharyngitis in susceptible individuals, usually children between the ages of 5 and 15 years.2 Amongst the children affected by ARF, the majority develop carditis, of whom approximately half develop permanent valvular lesions resulting in clinically apparent RHD.2 The acute damage to heart valves occurs by antigen mimicry. However, the pathogenesis of progression of valve lesions is debated. The most widely held belief is that progressive valve damage results from recurrent episodes of ARF. This is supported by
the natural history studies and constitutes the basis on which secondary penicillin prophylaxis is advised. However, there is evidence to suggest that chronic, sub-clinical inflammation may occur, and may potentially contribute to disease progression. This hypothesis is supported by the Bland and Jones data which showed that a significant proportion of patients developed mitral stenosis on follow-up over 20 years without having developed ARF recurrences in the interim period. Additionally, histopathological studies documenting the presence of active inflammation in excised left atrial appendages (LAA) in clinically and biochemically quiescent patients also point towards the presence of sub-clinical inflammation. Ga-67 scintigraphy has been studied only in a small number of patients with acute carditis. While several groups have studied peripheral blood lymphocytes and cytokine levels in patients with acute carditis and chronic RHD, no attempt has been made to correlate these results with histopathological evidence of inflammation. The aim of this study was to assess the diagnostic utility of biochemical markers of inflammation and Ga-67 scintigraphic imaging for detection of sub-clinical cardiac inflammation in patients with established RHD, who have no clinical or conventional biochemical evidence of rheumatic activity.

2. Methods

This was a prospective observational study. Patients older than 18 years who were scheduled for elective surgery (closed mitral valvotomy, mitral valve repair or mitral valve replacement) for chronic RHD were enrolled. The study protocol was approved by the institutional ethics committee and conforms to the ethical guidelines of the 1975 Declaration of Helsinki. All patients gave written informed consent. Subjects were excluded if they were pregnant or if they had clinical or laboratory evidence of rheumatic activity in the 3 months prior to enrolment, suspicion of concomitant primary myocardial disease (inflammatory myocarditis, dilated cardiomyopathy, or infiltrative myocardial disease), or coexistent systemic inflammatory disorders (inflammatory arthritis, connective tissue disorders and vasculitis).

Based on echocardiography, patients were divided into: combined stenotic lesions (isolated mitral stenosis + dominant stenotic lesions) and, combined regurgitant lesions (pure regurgitant lesions + dominant regurgitant lesions). Pre-operatively, Ga-67 scintigraphy scan was performed, and a blood sample was drawn for inflammatory markers. Both of these were done as close to the day of surgery as possible. Histopathological analysis of the LA appendages and other valve tissues was done within 48 h of excision. Fig. 1 outlines a schematic flow of patients through the study.

2.1. Ga-67 scintigraphy

Gallium-67 in a dose of 150–220 MBq (4–6 mCi) with a minimum dose of 9–18 MBq (0.25–0.5 mCi) was administered intravenously and images were acquired with a Millennium VG dual head gamma camera (GE Medical systems) equipped with a medium-energy parallel hole collimator. Planar images were obtained 24–72 h after injection of the radio-pharmaceutical. Once significant Ga-67 uptake was observed, SPECT images were acquired to localize the area of uptake, with a particular emphasis on imaging the LAA.

2.2. Inflammatory biomarkers

Blood samples were collected, and serum was separated and stored at −70 °C. Serum amyloid A (SAA), Interferon gamma (IFN-γ), Tumour Necrosis Factor alpha (TNF-α), Interleukin-2 (IL-2), Interleukin-6 (IL-6) and High Sensitivity C-Reactive Protein (hs-CRP) levels were determined by standard Enzyme-Linked Immunosorbent Assay (ELISA), using R&D Systems ELISA kits. Abnormal values were defined as per manufacturer instructions: hsCRP >3 mg/L, IL2 ≥ 10 pg/mL, IL6 ≥ 6.25 pg/mL, TNFα ≥25 pg/mL, IFNγ ≥12.5 pg/mL.

2.3. Histopathological examination of the excised specimens

Left atrial appendages in all patients and valve tissue in those patients who underwent valve replacement were excised at the time of surgery. The excised specimens were fixed in neutral buffered formalin for histopathologic examination. Representable sections from the specimens were processed in paraffin and blocks were made. The slides were evaluated under light microscopy using
hematoxylin and eosin staining. Masson’s trichrome staining is done in all samples processed at our center to highlight the presence of fibrosis and staining with Verhoeff’s Van Gieson when endocardial thickening is suspected. The presence of inflammation, characterized by lympho-mononuclear infiltrates and/or Aschoff bodies was used to define inflammation in our study. In the absence of well-defined criteria for inflammation in the left atrial appendage or valve tissue (unlike the Dallas criteria used to define inflammation in myocardium), the presence of inflammation was ascertained by an experienced cardiac pathologist (RR); presence of occasional lymphocytes was not considered positive for inflammation.

2.4. Statistical analysis

Continuous variables were expressed as mean ± standard deviation, and categorical variables were expressed as frequency (percentage). The association of biomarkers and clinical variables with the presence of histopathological inflammation was determined using univariable and multivariable logistic regression. All analyses were performed using Stata 15 (StataCorp, College Station, Texas). A p-value of <0.05 was considered to be statistically significant.

3. Results

During the study period, 93 consecutive chronic RHD patients who were eligible for inclusion in the study were enrolled. Data of 7 patients was incomplete, and 86 patients were available for the final analysis. Baseline characteristics are summarized in Table 1. Mean age of the study population was 34 years; 45% were females.

Histopathological examination of the excised valves and left atrial appendage detected lympho-mononuclear cell infiltration suggestive of chronic inflammation in 27 patients (31%) (Table 2). Aschoff bodies were not detected in any of the patients. Fibrosis was detected in 46 (53%) patients using Masson’s trichrome stain. None of the patients showed endocardial thickening. Representative histopathological specimens of left atrial appendage showing absence and presence of inflammation are shown in Fig. 2-A and 2-B.

Table 1

| Variable                          | n (%), or mean ± SD |
|-----------------------------------|--------------------|
| N                                 | 93                 |
| Age (Y)                           | 34.07 ± 11         |
| Females                           | 42 (45.1)          |

| Valve involvement                  |                    |
|-----------------------------------|--------------------|
| Isolated mitral stenosis          | 18 (19.4)          |
| Dominant stenotic lesion          | 48 (51.6)          |
| Pure regurgitant lesion           | 11 (11.8)          |
| Dominant regurgitant lesion       | 14 (15.1)          |
| Organic tricuspid valve disease   | 2 (2.1)            |

NYHA class (n = 72)

| NYHA class | n (%), or mean ± SD |
|------------|--------------------|
| I          | 1 (1.4)            |
| II         | 37 (51.4)          |
| III        | 31 (43.1)          |
| IV         | 3 (4.2)            |
| Congestive heart failure          | 10¹                 |
| Infective endocarditis            | 2 (2.2)             |

¹ Dominant stenotic lesion: severe mitral stenosis and/or aortic stenosis, with mild-moderate mitral regurgitation and/or aortic regurgitation.

Table 2

| Variable (N = 86) | n (%) |
|-------------------|-------|
| Histopathology    |       |
| Inflammation      | 27 (31.4) |
| Blood biomarkers  |       |
| hs-CRP            | 38 (44.2) |
| IL-2              | 77 (89.5) |
| IL-6              | 78 (90.7) |
| TNF α             | 68 (79.1) |
| IFN γ             | 70 (81.4) |

hs-CRP, High Sensitivity C-Reactive Protein; IL-2, Interleukin 2; IL-6, Interleukin 6; TNF α, Tumour Necrosis Factor Alpha; IFN γ, Interferon Gamma.

In this study, we found that histopathologically confirmed sub-clinical cardiac inflammation was found in nearly a third of patients with chronic RHD, who did not have any clinical evidence of rheumatic activity. Serum markers of inflammation, including circulating cytokines, were elevated in the majority of patients, but did not correlate with the presence of histologic inflammation. Regurgitant lesions were more likely to have sub-clinical inflammation, though this association was not statistically significant.

4. Discussion

Our results are consistent with Raizada et al who demonstrated the presence of inflammation in 25–33% of the RHD patients. Another study found a substantially larger proportion of patients with sub-clinical cardiac inflammation. Chopra et al noted that 28 of 50 patients showed evidence of leucocyte infiltration in the excised LA appendage tissue. It is plausible that younger patients may have a higher predilection to sub-clinical carditis. Patients in the study by Chopra et al were over a decade younger than those in our study (23 vs. 34 years). Moreover, among patients over the age of 30 years in that study, the proportion with sub-clinical inflammation was 29%, similar to our study. Likewise, average age in the Raizada study was above 30 years (32 years) with similar rate of histological inflammation (27%), which further supports this hypothesis.
4.2. Inflammatory biomarkers

Though serum markers of inflammation have been found to be elevated in patients with chronic RHD, the significance of this is not known. High-sensitivity CRP is the most commonly studied biomarker, and has been shown to correlate with the severity of valve disease.\(^{16–21}\) Elevation of plasma homocysteine,\(^{16}\) Pentraxin-3 (PTX3) levels\(^{19}\), and raised Neutrophil-to-Lymphocyte Ratio (NLR)\(^{20}\) have also been reported. However, some studies suggest that inflammatory biomarkers are elevated in ARF but not in RHD.\(^{22}\) None of the studies so far have attempted to ascertain the prevalence of biomarker elevation in RHD patients. Various intermediate molecules of the inflammatory cascade such as IFN-\(\gamma\), TNF-\(\alpha\) and interleukins are elevated in patients with RHD.\(^{8,9,14}\) In a Sudanese study, TNF-\(\alpha\) was elevated while IFN-\(\gamma\) and IL-10 levels were normal in RHD patients.\(^{23}\) Likewise, IL-17 and IL-23 levels were found to be significantly elevated in patients with RHD compared to age-matched controls.\(^{24}\) Recently, Soares et al highlighted the increased expression of IL-6 and TNF-\(\alpha\) in patients with more severe RHD.\(^{25}\) However, since all our patients had severe RHD (requiring surgery), determination of the association between biomarkers and disease severity was not possible in our study. A new inflammatory molecule, Tenascin-C, has been shown to correlate with myocardial inflammation\(^{26}\) and has been detected in the myocardium of RHD patients along with inflammatory cells.\(^{27}\)

Despite the large number of studies documenting the presence of inflammatory markers and cytokines in the serum of patients with chronic RHD, their relationship to sub-clinical carditis and disease progression has not hitherto been explored. In this study, evidence of biomarker elevation was seen in the majority of patients but was not discriminatory for the presence of histopathological evidence of carditis.

We do not understand the significance of elevated biomarkers in these patients. It could be that such nonspecific elevation is

---

**Table 3**

| Biochemical markers | Inflammation | \(p\) value | Odds ratio — Uni variable analysis (95% CI) | Odds ratio — Multi variable (95% CI) |
|---------------------|--------------|-------------|------------------------------------------|-----------------------------------|
| hs-CRP\(^{p}\)       | Normal       | 33          | 15                                       | 0.974 1.01 (0.40–2.53) 0.75 (0.27–2.04) |
|                     | Elevated     | 26          | 12                                       | 0.713 1.68 (0.32–8.69) 1.26 (0.21–7.41) |
| IL-2                | Normal       | 7           | 2                                        | 0.426 3.49 (0.40–29.97) 3.44 (0.36–32.27) |
|                     | Elevated     | 52          | 25                                       | 0.161 2.72 (0.71–10.37) 2.49 (0.64–9.71) |
| IL-6                | Normal       | 7           | 1                                        | 0.371 2.26 (0.58–8.71) 2.26 (0.54–9.39) |
|                     | Elevated     | 52          | 26                                       |                                                   |
| TNF-\(\alpha\)      | Normal       | 15          | 3                                        | 0.161 3.49 (0.40–29.97) 3.44 (0.36–32.27) |
|                     | Elevated     | 44          | 24                                       | 0.215 2.72 (0.71–10.37) 2.49 (0.64–9.71) |
| IFN-\(\gamma\)      | Normal       | 13          | 3                                        | 0.371 2.26 (0.58–8.71) 2.26 (0.54–9.39) |
|                     | Elevated     | 46          | 24                                       |                                                   |

*hs-CRP, High Sensitivity C-Reactive Protein; IL-2, Interleukin 2; IL-6, Interleukin 6; TNF-\(\alpha\), Tumour Necrosis Factor Alpha; IFN-\(\gamma\), Interferon Gamma.
Normal values: hsCRP \(\leq\) 3 mg/L, IL2 <10 pg/mL, IL6 <6.25 pg/mL, TNF\(\alpha\) <25 pg/mL, IFN\(\gamma\) <12.5 pg/mL.

---

**Table 4**

| Valve lesions | n  | Inflammation | \(p\) value | Odds ratio - Uni variable analysis (95% CI) |
|---------------|----|--------------|-------------|------------------------------------------|
| Isolated Mitral Stenosis | 17 | 14           | 3           | 1                                         |
| Dominant stenotic lesion\(^{a}\) | 44 | 29           | 15          | 0.215 2.41 (0.59–9.73)                   |
| Pure regurgitant lesion\(^{b}\) | 11 | 8            | 3           | 0.547 1.75 (0.28–10.81)                  |
| Dominant regurgitant lesion\(^{c}\) | 14 | 8            | 6           | 0.133 3.5 (0.68–17.96)                   |

*Dominant stenotic lesion: severe mitral stenosis and/or aortic stenosis, with mild-moderate mitral regurgitation and/or aortic regurgitation.

\(^{a}\) Pure regurgitant lesion: moderate-severe mitral regurgitation and/or aortic regurgitation with no mitral stenosis or aortic stenosis.

\(^{c}\) Dominant regurgitant lesion: severe mitral regurgitation and/or aortic regurgitation, with mild-moderate mitral stenosis and/or aortic stenosis.
observed in patients with any longstanding disease states, akin to the elevations of hsCRP seen in patients with chronic coronary syndrome. Large prospective studies are needed to assess the importance of biomarker elevations on disease progression and prognosis in RHD.

4.3. Radionuclide imaging

Previous attempts at radionuclide-based inflammation imaging in RHD have all been in patients with ARF. Calegaro et al performed Ga-67 imaging in 30 patients with rheumatic fever carditis, where it was noted to have a 93.5% sensitivity for detecting carditis. There was a 39% greater uptake of Ga-67 in patients with carditis when compared to those without carditis. Narula and colleagues used Indium labeled antimyosin antibodies and demonstrated a sensitivity of 80% for diagnosing acute rheumatic activity. Gallium may be a better tracer than Indium because rheumatic carditis is only rarely associated with myocardial necrosis. We discontinued Ga-67 scanning after 15 patients because of poor image quality and inability to detect activity even among patients who had documented inflammation. Ga-67 scintigraphy may not be sensitive enough to detect the low level of inflammation present in chronic RHD.

4.4. Other imaging modalities

Using late gadolinium enhancement (LGE) as a surrogate for myocardial fibrosis, cardiac MRI (CMR) has been utilized in RHD patients with varying results. Significant myocardial fibrosis was shown in RHD patients with severe MS, compared to another study of RHD patients with predominant MR where fibrosis on CMR was found to be relatively uncommon. Similar studies looking at myocardial edema or inflammation have not been carried out till date. F-18 FDG PET/CT is an upcoming modality for inflammation detection in a myriad of systemic inflammatory disorders. However, the only study which looked at its role in rheumatic heart disease showed no difference in the imaging pattern between chronic RHD patients and controls.

4.5. Study limitations

We used simple hematoxylin and eosin (H&E) staining for detection of inflammation. It is possible that immunohistochemical staining using CD3, CD4 and CD8 antibodies may have helped to better characterize the inflammation detected. Also, we did not include a control group in our study.

5. Conclusion

Histopathologic evidence of inflammation is commonly present in the heart valve and LA appendage specimens retrieved from patients with chronic RHD who do not have clinical rheumatic activity. Serum levels of inflammatory biomarkers are also commonly elevated in these patients but do not correlate with the presence of cardiac inflammation. Better ways to detect sub-clinical inflammation in chronic RHD may pave the way to understanding its role in disease progression.

6. One-line key messages

What is already known?

- Sub-clinical inflammation is often seen in patients with chronic RHD

What this study adds?
• Backspace Conventional inflammatory biomarkers are elevated in the majority of patients with chronic RHD, but do not correlate with the presence of histologic inflammation.

Declaration of competing interest

None declared.

Acknowledgement of grant support

This work was supported by the Department of Biotechnology (DBT), New Delhi, India. DBT was not involved in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

References

1. Watkins DA, Johnson CO, Colquhoun SM, et al. Global, regional, and national burden of rheumatic heart disease. N Engl J Med. 2017;377:713–722, 1990–2015.
2. Karthikeyan G, Guillerme L. Acute rheumatic fever. Lancet. 2018;392:161–174.
3. Feinstein AR, Wood HF, Spagnuolo M, et al. Rheumatic fever in children and adolescents. A long-term epidemiologic study of subsequent prophylaxis, streptococcal infections, and sequelae. VII. Cardiac changes and sequelae. Ann Intern Med. 1964;60:87–123.
4. Marcus RH, Sareli P, Pocock WA, Barlow JB. The spectrum of severe rheumatic mitral valve disease in a developing country. Correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae. Ann Intern Med. 1994;120:177–183.
5. Bland EF, Ducket Jones T. Rheumatic fever and rheumatic heart disease; a twenty year report on 1000 patients followed since childhood. Circulation. 1951;4:836–843.
6. Chopra P, Narula J, Kumar AS, Sachdeva S, Bhatia ML. Immunohistochemical characterisation of Aschoff nodes and endomyocardial inflammatory infil- trates in left atrial appendages from patients with chronic rheumatic heart disease. Int J Cardiol. 1980;3:371–105.
7. Ju Calearo, de Carvalho AC, Campos ER, Medeiros M, Gomes Ede F, Gallium-67 in rheumatic fever: preliminary report. Arq Bras Cardiol. 1991;56:487–492.
8. Morris K, Cohman CW, Wahi PL, Anand IS, Ganguly NK. Enhancement of IL-1, IL-2 and active rheumatic heart disease; a prospective study. Clin Exp Immunol. 1993;91:429–436.
9. Yegiu O, Ocukon M, Ergiu H. Cytokines in acute rheumatic fever. Eur J Pediatr. 1997;156:23–29.
10. Bhatnagar A, Grover A, Ganguly N. Superantigen-induced T cell responses in acute rheumatic fever and chronic rheumatic heart disease patients. Clin Exp Immunol. 1999;116:100–106.
11. Guillerme L, Oshiro SE, Fae KC, et al. T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun. 2001;69:5345–5351.
12. Guillerme L, Cury P, Demarchi LMF, et al. Rheumatic heart disease: proin- flammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol. 2004;165:1583–1591.
13. Narin N, Kutukculer N, Ozyurek R, Bakiler AR, Parlar A, Arcaosy M. Lymphocyte subsets and plasma IL-1 alpha, IL-2, and TNF-alpha concentrations in acute rheumatic fever and chronic rheumatic heart disease. Clin Immunol Immunopathol. 1995;77:172–176.
14. Davutoğlu V, Celik A, Aksoy M. Contribution of selected serum inflammatory mediators to the progression of chronic rheumatic valve disease, subsequent valve calcification and NYHA functional class. J Heart Valve Dis. 2005;14:251–256.
15. Raiarda V, Williams RC, Chopra P, et al. Tissue distribution of lymphocytes in rheumatic heart valves as defined by monoclonal anti-T cell antibodies. Am J Med. 1983;74:90–96.
16. Attar A, Marzban P, Moaref A, Aghasadeghi K. The association of plasma high-sensitivity C-reactive protein level with rheumatic heart disease: the possible role of inflammation. Indian Heart J. 2018;70:346–349.
17. Gollakzi Z, Ucar O, Keles T, et al. Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease: evidence of ongoing inflammation. Eur J Heart Fail. 2002;4:593–595.
18. Habeeb NM, Al Haddad IS. Ongoing inflammation in children with rheumatic heart disease. Cardiol Young. 2011;21:324–339.
19. Polat N, Yildiz A, Alan S, Toprac N. Association of pentraxin-3 with the severity of rheumatic mitral valve stenosis. Acta Cardiol. 2015;70:409–413.
20. Akboga MK, Akyel A, Sahinarslan A, et al. Neutrophil-to-lymphocyte ratio is increased in patients with rheumatic mitral valve stenosis? Anatol J Cardioil. 2015;15:380–384.
21. Alyan O, Metin F, Kacmaz F, et al. High levels of high sensitivity C-reactive protein predict the progression of chronic rheumatic mitral stenosis. J Thromb Thrombolysis. 2009;28:63–69.
22. Karasiz T, Baysal T, Sarp F, Alp H, Mehmetoglu I. Increased ischaemia-modified albumin is associated with inflammation in acute rheumatic fever. Cardiol Young. 2014;24:430–436.
23. Ali SM, Eldaim IN, Osman SH, Bakhte SM. Clinical and echocardiographic features of children with rheumatic heart disease and their serum cytokine profile. Pan Afr Med J. 2012;13:36.
24. Bilik MZ, Kaplan I, Polat N, et al. Serum levels of IL-17 and IL-23 in patients with rheumatic mitral stenosis. Medicine. 2016;95, e3562.
25. Diamantino Soares A, Araujo Passos L, Sable C, et al. Circulating cytokines predict severity of rheumatic heart disease. Int J Cardiol. 2019;289:107–109.
26. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, et al. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol. 2002;197:388–394.
27. Shiha M, Sugano Y, Ikekawa Y, et al. Pathohistological evidence of smoldering inflammation in rheumatic heart disease with massive left atrial calcification. Intern Med. 2016;55:791–754.
28. Narula J, Khaw BA, DC GW, et al. Diagnostic accuracy of antinmyosin scintig- raphy in suspected myocarditis. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol. 1996;3:371–381.
29. Santos-Gallego CG, Glasgow Y, Benaceraf M, et al. Mild rheumatic valvular heart disease is associated with interstitial myocardial fibrosis: a T1 mapping study. J Am Coll Cardiol. 2019;69:1620.
30. Megn R, Nethononda L, Liebhaber E, Dax-Peek T, Peters F, Essop M. Assessment of myocardial fibrosis by late gadolinium enhancement imaging and biomarkers of collagen metabolism in chronic rheumatic mitral regurgitation. Cardiovasc J Afr. 2018;29:150–154.
31. Nagesh CM, Saxena A, Patel C, Karunanithi S, Nadig M, Malhotra A. The role of 18F fluorodeoxyglucose positron emission tomography (18F- FDG PET) in children with rheumatic carditis and chronic rheumatic heart disease. Nucl Med Rev Cent East Eur. 2015;18:25–28.